Abstract
This chapter examines the role of the coagulation system in cancer. While the role of a prothrombotic state was linked to cancer development many years ago, effective targeting of mediators of coagulation is not yet an element of cancer therapy. In the last decade, multiple novel anticoagulants have been approved for use in the prevention or treatment of thrombotic conditions. The presence of a larger armamentarium of medications with fewer bleeding side effects makes them suitable adjuncts in the multimodal treatment of cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lima LG, Monteiro RQ. Activation of blood coagulation in cancer: implications for tumour progression. Biosci Rep. 2013;33(5):e00064.
Otten HM, Mathijssen J, ten Cate H, Soesan M, Inghels M, Richel DJ, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med. 2004;164(2):190–4.
Im JH, Fu W, Wang H, Bhatia SK, Hammer DA, Kowalska MA, et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 2004;64(23):8613–9.
ten Cate H, Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiol Haemost Thromb. 2008;36(3-4):122–30.
Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001;345(26):1890–1900.
Howlader N Noone A, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ Cronin K. SEER cancer statistics review, 1975–2011 posted to the SEER web site, April 2014. based on November 2013 SEER data submission.
Bernstein JM, Bernstein CR, West CM, Homer JJ. Molecular and cellular processes underlying the hallmarks of head and neck cancer. Eur Arch Otorhinolaryngol. 2013;270(10):2585–93.
Liao CT, Wallace CG, Lee LY, Hsueh C, Lin CY, Fan KH, et al. Clinical evidence of field cancerization in patients with oral cavity cancer in a betel quid chewing area. Oral Oncol. 2014;50(8):721–31.
Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781–9.
Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6(5):963–8.
Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309–22.
Rachidi S, Wallace K, Day TA, Alberg AJ, Li Z. Lower circulating platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma. J Hematol Oncol. 2014;7:65.
Bao YN, Cao X, Luo DH, Sun R, Peng LX, Wang L, et al. Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis. Cell Cycle. 2014;13(12):1958–69.
Falanga A. Thrombophilia in cancer. Semin Thromb Hemost. 2005;31(1):104–10.
Zacharski LR, Memoli VA, Ornstein DL, Rousseau SM, Kisiel W, Kudryk BJ. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst. 1993;85(15):1225–30.
Gale AJ, Gordon SG. Update on tumor cell procoagulant factors. Acta Haematol. 2001;106(1-2):25–32.
Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002;3(1):27–34.
Dvorak HF. Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol. 2003;162(6):1747–57.
Fernandez PM, Patierno SR, Rickles FR. Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost. 2004;30(1):31–44.
Sahni A, Simpson-Haidaris PJ, Sahni SK, Vaday GG, Francis CW. Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2). J Thromb Haemost. 2008;6(1):176–83.
Lalla RV, Goralnick SJ, Tanzer ML, Kreutzer DL. Fibrin induces IL-8 expression from human oral squamous cell carcinoma cells. Oral Oncol. 2001;37(3):234–42.
Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96(10):3302–9.
Shu YJ, Weng H, Bao RF, Wu XS, Ding Q, Cao Y, et al. Clinical and prognostic significance of preoperative plasma hyperfibrinogenemia in gallbladder cancer patients following surgical resection: a retrospective and in vitro study. BMC Cancer. 2014;14:566.
Bruggemann LW, Versteeg HH, Niers TM, Reitsma PH, Spek CA. Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J Cell Mol Med. 2008;12(6B):2622–7.
Battistelli S, Stefanoni M, Genovese A, Vittoria A, Cappelli R, Roviello F. Prevalence of factor V Leiden and prothrombin G20210A in patients with gastric cancer. World J Gastroenterol. 2006;12(26):4179–80.
Vairaktaris E, Yapijakis C, Wiltfang J, Ries J, Vylliotis A, Derka S, et al. Are factor V and prothrombin mutations associated with increased risk of oral cancer? Anticancer Res. 2005;25(3c):2561–5.
Vossen CY, Hoffmeister M, Chang-Claude JC, Rosendaal FR, Brenner H. Clotting factor gene polymorphisms and colorectal cancer risk. J Clin Oncol. 2011;29(13):1722–7.
Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 2006;10(5):355–62.
Koga Y, Manabe S, Aihara Y, Sato R, Tsumura R, Iwafuji H, et al. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts. Int J Cancer. 2015;137(6):1457–66.
Langer F, Amirkhosravi A, Ingersoll SB, Walker JM, Spath B, Eifrig B, et al. Experimental metastasis and primary tumor growth in mice with hemophilia A. J Thromb Haemost. 2006;4(5):1056–62.
Miesbach W, Seifried E. Does haemophilia influence cancer-related mortality in HIV-negative patients? Haemophilia. 2011;17(1):55–60.
Huang YC, Tsan YT, Chan WC, Wang JD, Chu WM, Fu YC, et al. Incidence and survival of cancers among 1,054 hemophilia patients: a nationwide and 14-year cohort study. Am J Hematol. 2015;90(4):E55–9.
Palumbo JS, Barney KA, Blevins EA, Shaw MA, Mishra A, Flick MJ, et al. Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost. 2008;6(5):812–9.
Kwaan HC, Mazar AP, McMahon BJ. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost. 2013;39(4):382–91.
Bezuhly M, Cullen R, Esmon CT, Morris SF, West KA, Johnston B, et al. Role of activated protein C and its receptor in inhibition of tumor metastasis. Blood. 2009;113(14):3371–4.
Ruf W, Schaffner F. Role of the protein C receptor in cancer progression. Thromb Res. 2014;133 Suppl 2:S85–9.
Mochizuki S, Soejima K, Shimoda M, Abe H, Sasaki A, Okano HJ, et al. Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. J Natl Cancer Inst. 2012;104(12):906–22.
Zucker S, Cao J. New wrinkle between cancer and blood coagulation: metastasis and cleavage of von Willebrand factor by ADAM28. J Natl Cancer Inst. 2012;104(12):887–8.
Luo GP, Ni B, Yang X, Wu YZ. von Willebrand factor: more than a regulator of hemostasis and thrombosis. Acta Haematol. 2012;128(3):158–69.
Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TA, Sutton RE, et al. Endothelial von Willebrand factor regulates angiogenesis. Blood. 2011;117(3):1071–80.
Terraube V, Pendu R, Baruch D, Gebbink MF, Meyer D, Lenting PJ, et al. Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost. 2006;4(3):519–26.
Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123–34.
Paneesha S, McManus A, Arya R, Scriven N, Farren T, Nokes T, et al. Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics. Thromb Haemost. 2010;103(2):338–43.
Hakelius M, Koskela A, Ivarsson M, Grenman R, Rubin K, Gerdin B, et al. Keratinocytes and head and neck squamous cell carcinoma cells regulate urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in fibroblasts. Anticancer Res. 2013;33(8):3113–8.
Wojtukiewicz MZ, Zacharski LR, Rucinska M, Zimnoch L, Jaromin J, Rozanska-Kudelska M, et al. Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma. Thromb Haemost. 1999;82(6):1659–62.
Buchs AE, Zehavi S, Sher O, Yeheskely E, Muggia-Sulam M, Sherman Y, et al. Heparanase, galectin-3, and tissue factor mRNA are expressed in benign neoplasms of the thyroid. Endocrine. 2003;22(2):81–4.
Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med. 2004;10(5):502–9.
Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994;94(3):1320–7.
Pabinger I, Posch F. Flamethrowers: blood cells and cancer thrombosis risk. Hematology Am Soc Hematol Educ Program. 2014;2014(1):410–7.
Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–5.
Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers Jr DD, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010;107(36):15880–5.
Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fuchs TA, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A. 2012;109(32):13076–81.
Martinod K, Demers M, Fuchs TA, Wong SL, Brill A, Gallant M, et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci U S A. 2013;110(21):8674–9.
Yapijakis C, Bramos A, Nixon AM, Ragos V, Vairaktaris E. The interplay between hemostasis and malignancy: the oral cancer paradigm. Anticancer Res. 2012;32(5):1791–800.
Vairaktaris E, Serefoglou Z, Avgoustidis D, Yapijakis C, Critselis E, Vylliotis A, et al. Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer. Oral Oncol. 2009;45(3):247–53.
Weng CJ, Lin CW, Chung TT, Tsai CM, Chen MK, Yang SF. Impact of uPA system gene polymorphisms on the susceptibility of environmental factors to carcinogenesis and the development of clinicopathology of oral cancer. Ann Surg Oncol. 2011;18(3):805–12.
Gao S, Nielsen BS, Krogdahl A, Sorensen JA, Tagesen J, Dabelsteen S, et al. Epigenetic alterations of the SERPINE1 gene in oral squamous cell carcinomas and normal oral mucosa. Genes Chromosomes Cancer. 2010;49(6):526–38.
Yoshino I, Kometani T, Shoji F, Osoegawa A, Ohba T, Kouso H, et al. Induction of epithelial-mesenchymal transition-related genes by benzo[a]pyrene in lung cancer cells. Cancer. 2007;110(2):369–74.
Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost. 2004;2(12):2107–14.
Nash GF, Walsh DC, Kakkar AK. The role of the coagulation system in tumour angiogenesis. Lancet Oncol. 2001;2(10):608–13.
Chang MC, Chan CP, Ho YS, Lee JJ, Lin PS, Lin BR, et al. Signaling pathways for induction of platelet aggregation by SAS tongue cancer cells – a mechanism of hematogenous metastasis. J Oral Pathol Med. 2009;38(5):434–40.
Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23(6):1403–15.
Zou H, Yue W, Yu WK, Liu D, Fong CC, Zhao J, et al. Microfluidic platform for studying chemotaxis of adhesive cells revealed a gradient-dependent migration and acceleration of cancer stem cells. Anal Chem. 2015;87(14):7098–108.
Masters JR. HeLa cells 50 years on: the good, the bad and the ugly. Nat Rev Cancer. 2002;2(4):315–9.
Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010;10(4):241–53.
Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst. 2013;105(7):452–8.
Christopher D, Lansford RG, Henning B, Somers KD, Yoon KS, Whiteside TL, Clayman GL, Welkoborsky HJ, Carey TE. Head and neck cancers. In: Masters JRWP B, editor. Human cell culture, vol. 2. Boston and London: Kluwer; 1999. p. 185–255.
Haycock JW. 3D cell culture: a review of current approaches and techniques. Methods Mol Biol. 2011;695:1–15.
Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science. 1992;255(5052):1707–10.
Abhold EL, Kiang A, Rahimy E, Kuo SZ, Wang-Rodriguez J, Lopez JP, et al. EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells. PLoS One. 2012;7(2):e32459.
Wu J, Mu Q, Thiviyanathan V, Annapragada A, Vigneswaran N. Cancer stem cells are enriched in Fanconi anemia head and neck squamous cell carcinomas. Int J Oncol. 2014;45(6):2365–72.
Lee YC, Yu CC, Lan C, Lee CH, Lee HT, Kuo YL, et al. Plasminogen activator inhibitor-1 as regulator of tumor-initiating cell properties in head and neck cancers. Head Neck. 2015.
Shimosato Y, Kameya T, Nagai K, Hirohashi S, Koide T, Hayashi H, et al. Transplantation of human tumors in nude mice. J Natl Cancer Inst. 1976;56(6):1251–60.
Myers JN, Holsinger FC, Jasser SA, Bekele BN, Fidler IJ. An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin Cancer Res. 2002;8(1):293–8.
White R, Rose K, Zon L. Zebrafish cancer: the state of the art and the path forward. Nat Rev Cancer. 2013;13(9):624–36.
MacRae CA, Peterson RT. Zebrafish as tools for drug discovery. Nat Rev Drug Discov. 2015;14(10):721–31.
Kretz CA, Weyand AC, Shavit JA. Modeling disorders of blood coagulation in the Zebrafish. Curr Pathobiol Rep. 2015;3(2):155–61.
Tat J, Liu M, Wen XY. Zebrafish cancer and metastasis models for in vivo drug discovery. Drug Discov Today Technol. 2013;10(1):e83–9.
White RM, Sessa A, Burke C, Bowman T, LeBlanc J, Ceol C, et al. Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell. 2008;2(2):183–9.
Jung DW, Kim J, Che ZM, Oh ES, Kim G, Eom SH, et al. A triazine compound S06 inhibits proinvasive crosstalk between carcinoma cells and stromal fibroblasts via binding to heat shock protein 90. Chem Biol. 2011;18(12):1581–90.
Xia Y, Song X, Li D, Ye T, Xu Y, Lin H, et al. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models. Sci Rep. 2014;4:6031.
Babu PV, Mukherjee S, Deora GS, Chennubhotla KS, Medisetti R, Yellanki S, et al. Ligand/PTC-free intramolecular Heck reaction: synthesis of pyrroloquinoxalines and their evaluation against PDE4/luciferase/oral cancer cell growth in vitro and zebrafish in vivo. Org Biomol Chem. 2013;11(39):6680–5.
Xiong P, Xiao LY, Yang R, Guo Q, Zhao YQ, Li W, et al. Flotillin-1 promotes cell growth and metastasis in oral squamous cell carcinoma. Neoplasma. 2013;60(4):395–405.
Lee BS, Kang SU, Hwang HS, Kim YS, Sung ES, Shin YS, et al. An agonistic antibody to human death receptor 4 induces apoptotic cell death in head and neck cancer cells through mitochondrial ROS generation. Cancer Lett. 2012;322(1):45–57.
Tang Q, Abdelfattah NS, Blackburn JS, Moore JC, Martinez SA, Moore FE, et al. Optimized cell transplantation using adult rag2 mutant zebrafish. Nat Methods. 2014;11(8):821–4.
Kleinstiver BP, Prew MS, Tsai SQ, Topkar VV, Nguyen NT, Zheng Z, et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature. 2015;523(7561):481–5.
Vo AH, Swaroop A, Liu Y, Norris ZG, Shavit JA. Loss of fibrinogen in zebrafish results in symptoms consistent with human hypofibrinogenemia. PLoS One. 2013;8(9):e74682.
Liu Y, Kretz CA, Maeder ML, Richter CE, Tsao P, Vo AH, et al. Targeted mutagenesis of zebrafish antithrombin III triggers disseminated intravascular coagulation and thrombosis, revealing insight into function. Blood. 2014;124(1):142–50.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Jesudas, R. et al. (2016). Targeting Coagulation Mediators in Head and Neck Cancer. In: M. Fribley, A. (eds) Targeting Oral Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-27647-2_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-27647-2_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-27645-8
Online ISBN: 978-3-319-27647-2
eBook Packages: MedicineMedicine (R0)